Title : Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.

Pub. Date : 2022 Mar 30

PMID : 35406532






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The Bruton tyrosine kinase inhibitor ibrutinib, given as monotherapy or combined with other molecules, has proven effective in numerous B-cell lymphomas. ibrutinib Bruton tyrosine kinase Homo sapiens